Zydus to Enter Global Biologics CDMO Business Plans to Acquire Agenus' U.S. Manufacturing Facilities to Accelerate Development of Innovative Therapies
BusinessWire India
New Jersey [US]/ Ahmedabad (Gujarat) [India], June 3: Zydus Lifesciences Ltd. (including its subsidiaries/affiliates, hereafter referred to as "Zydus) today announced its entry into the global biologics contract development and manufacturing organization (CDMO) business through its plan to acquire Agenus Inc.'s (Nasdaq: AGEN) U.S.-based biologics CMC facilities. This acquisition marks Zydus' strategic investment in U.S.-based manufacturing for biologics thereby adding a sustainable growth driver for the group. Agenus Inc. is a clinical-stage immuno-oncology company committed to developing immune therapies that effectively combat cancer.
Under the terms of the agreement, Zydus will acquire two state-of-the-art biologics manufacturing facilities from Agenus in Emeryville and Berkeley, California (US) for an upfront consideration of US$75 million and contingent payment of US$50 million to be paid over three years subject to achievement of certain revenue milestone. This acquisition provides Zydus immediate access to advanced biologics manufacturing capabilities and establishes a key presence in California, a leading global biotechnology hub. This strategic move enables Zydus to leverage supply chain dynamics and a favourable geopolitical environment to expand its reach in the U.S. and globally. With this acquisition Zydus will now become a one stop solution provider across the entire development spectrum of biologics, right from pre-clinical to toxicology studies, clinical development and now manufacturing.
Zydus' CDMO business will operate as an independent entity and will house the acquired manufacturing capabilities. The facilities come with an experienced professional team with strong capabilities and requisite industry expertise to deliver high-quality biologics development and manufacturing services to global biotech and pharmaceutical companies. As a part of transaction Zydus will become an exclusive contract manufacturer for Agenus and will provide manufacturing services for clinical and commercial supply of two identified Phase-3 ready immuno-oncology products, Botensilimab (BOT) and Balstilimab (BAL). Zydus will also have first right of negotiation to manufacture any of the future pipeline products developed by Agenus. Zydus intends to further expand the team and help create new jobs in the region and contribute to the local economy.
Speaking on the development, Dr. Sharvil Patel, Managing Director, Zydus Lifesciences Ltd. said, "The acquisition will give Zydus a strategic foothold in the U.S. for biologics manufacturing in the global hub for biotech innovation, California. It will enhance our ability to partner with innovation-centric entities, advancing new products and prioritizing patient-centric solutions. This move strengthens our long-term biologics vision and positions us to better serve the evolving needs of the global biopharmaceutical industry."
The global biologics CDMO market is experiencing significant growth, driven by the increasing complexity of therapies, the rise of biologics in clinical pipelines, and a growing number of emerging biotech companies lacking internal manufacturing capabilities. According to market.us, the Global Biologics CDMO Market Size is expected to be worth around US$ 84.9 Billion by 2034, growing at a CAGR of 15.7% between 2025 to 2034. As demand surges for reliable, agile, and scalable partners, Zydus' entry into this space positions it to tap into significant long-term growth opportunities and support innovation across the global biopharmaceutical landscape.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hindu
an hour ago
- The Hindu
Dr. Reddy's, Alvotech to co-develop, market biosimilar of Merck's cancer drug Keytruda
Pharma major Dr. Reddy's Laboratories and Nasdaq-listed global biotech firm Alvotech will co-develop, manufacture and commercialise a biosimilar candidate to Merck's cancer drug Keytruda (pembrolizumab) for global markets. They will be jointly responsible for developing and manufacturing the biosimilar candidate and sharing costs as well as the responsibilities. 'Subject to certain exceptions, each party will have the right to commercialise the product globally,' Dr. Reddy's and Alvotech said on Thursday (June 5, 2025) in a joint statement announcing the signing of a licence agreement. The collaboration will combine their proven capabilities in biosimilars thus speeding up the development process and extending global reach for the biosimilar candidate. A registered trademark of Merck Sharp & Dohme Corp, Keytruda is indicated for the treatment of numerous cancer types. In 2024, the worldwide sales of Keytruda were $29.5 billion. Oncology top focus therapy 'Oncology has been a top focus therapy area for us and this collaboration will further enhance our capabilities in oncology, as pembrolizumab currently represents one of the most critical therapies in immuno-oncology,' Dr. Reddy's CEO Erez Israeli said. Alvotech chairman and CEO Robert Wessman said 'we are pleased to enter into this collaboration for pembrolizumab with Dr. Reddy's. This agreement demonstrates Alvotech's ability to leverage its dedicated R&D and manufacturing platform for biosimilars, accelerating the expansion of our pipeline by pursuing growing global markets.'
Business Standard
2 hours ago
- Business Standard
U.S. Stocks Mixed as ADP Jobs Data Misses; Trump Pressures Fed, Bond Yields Slide
Weaker-than-expected job growth and a surprise services sector contraction weighed on markets; Trump calls for rate cuts, while housing and chip stocks rally. The Dow dipped 91.90 points or 0.2 percent to 42,427.74, the S&P 500 inched up 0.44 points or less than a tenth of a percent to 5,970.81 and the Nasdaq rose 61.53 points or 0.3 percent to 19,460.49. payroll processor ADP released a report showing much weaker than expected private sector job growth in the month of May. It also said private sector employment rose by 37,000 jobs in May after climbing by a downwardly revised 60,000 jobs in April. Following the release of the ADP report, President Donald Trump took to Truth Social urging Fed Chair Jerome Powell to lower interest rates. Institute for Supply Management released a report showing service sector activity in the U.S. unexpectedly saw a slight contraction in the month of May. It also said its services PMI fell to 49.9 in May from 51.6 in April, with a reading below 50 indicating contraction. The Fed is still widely expected to leave interest rates unchanged at its next meeting later this month, with CME Group's FedWatch Tool currently indicating a 95.6 percent chance the central bank will leave rates unchanged. Broader markets showed a lacklustre performance, housing stocks moved significantly higher on the day, driving the Philadelphia Housing Sector Index up by 1.7 percent. Semiconductor stocks were considerably strong, as reflected by the 1.4 percent gain posted by the Philadelphia Semiconductor Index. Gold and pharmaceutical stocks also saw some strength on the day, while energy stocks came under pressure as the price of crude oil gave back ground following a two-day surge. Asia-Pacific stocks moved mostly higher. Japan's Nikkei 225 Index climbed by 0.8 percent while China's Shanghai Composite Index rose by 0.4 percent. The major European markets also moved upside. The German DAX Index advanced by 0.8 percent, the French CAC 40 Index increased by 0.5 percent and the U.K.'s FTSE 100 Index edged up by 0.2 percent. In the bond market, treasuries moved sharply higher in reaction to the latest U.S. economic data. As a result, the yield on the benchmark ten-year note, which moves opposite of its price, plunged 9.5 bps to 4.36 percent.
Business Standard
4 hours ago
- Business Standard
Alvotech and Dr Reddy's enter into collaboration and license agreement for pembrolizumab
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide (Alvotech), and Dr. Reddy's Laboratories announced that the companies have entered into a collaboration and license agreement to co develop, manufacture and commercialize a biosimilar candidate to Keytruda (pembrolizumab) for global markets. Keytruda (pembrolizumab) is indicated for the treatment of numerous cancer types. In 2024, worldwide sales of Keytruda were US$29.5 billion [1]. The collaboration combines Dr. Reddy's and Alvotech's proven capabilities in biosimilars, thereby, speeding up the development process and extending the global reach for this biosimilar candidate. Under the terms of the agreement, the parties will be jointly responsible for developing and manufacturing the biosimilar candidate and sharing costs and responsibilities. Subject to certain exceptions, each party will have the right to commercialize the product globally.
